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Editorial on the Research Topic
Transfusion Medicine and Blood
Transfusion medicine is in perpetual evolution and has faced several challenges since the
seventeenth century. Nevertheless, it is a relatively new specialty based on an old and simple concept
that is transferring blood from an individual to another one. The history of the discipline is quite
rich, the first steps being associated with killing patients (1) (due to numerous reasons sometimes
not necessarily related to transfusion) notably because of acute hemolytic reactions related to ABO
incompatibilities (beyond xenotransfusion). Indeed, before 1900, the blood groups were unknown
(2). Over the years, transfusion medicine evolved from a dangerous concept to a reality, and was
really the first example of personalized medicine when transfusion was performed arm to arm: the
donor and the recipient were in the same room, with a single doctor caring both individuals as well
as the process (3). Furthermore, the blood transfused was a non-denaturized product: it was “true”
blood, “pure” blood, without any process and storage lesions.
Nowadays, blood transfusion is the paradigm of both precision and personalized medicine: (i)
blood or blood components are collected from donors with well characterized blood groups and/or
HLA geno-phenotypes and or sometimes for particular (non)-reactivity with specific pathogens
such as hepatitis E or cytomegalovirus, (ii) blood is separated in its different components that
are red blood cells (RBCs), platelets, plasma, and other therapeutics. Whatever the “philosophic
consideration,” more than 100 million of donations per year are performed worldwide and, even
if at risk, transfused blood products save lives. Nevertheless, the pressure in terms of efficacy,
safety, blood management, and cost constrains currently pushes a further evolution of transfusion
medicine. Research in transfusion medicine is diverse, interdisciplinary, and regularly proposes
innovation along the whole transfusion chain, involving every stage from the donors to the
recipients. Each step (donors and blood collection, screening, preparation, storage, transfusion as
well as post-transfusion survey) has been considered in order to improve safety, quality, and benefit
to the patients. Some of these aspects are highlighted by the diversity of the published articles in this
research topic and introduced below.
GLOBAL AND INDIVIDUAL DIVERSITY
The diversity in transfusion medicine is real (beyond the blood groups), and this diversity is
present at different levels. Socio-political and economical aspects of transfusion medicine are of
primary importance when western countries participate to the development of blood collection
and processing in lower to upper middle-income countries. It is the case in Eastern/Southern
Mediterranean countries where surveys are currently ongoing to address diverse issues in
transfusion medicine, as reviewed by Haddad et al. The diversity is also dependent on the donors
Prudent et al. Editorial: Transfusion Medicine and Blood
(genetically or not), on the patients, and on the processing
and storage, where differences in blood component quality were
reported. Garraud and Tissot discussed these differences and
similarities, and the potential consequences in transfusion.
SAFETY AND INFECTIOUS DISEASE
AGENTS
Safety of blood transfusion is achieved at different steps of
the chain. The first link is the donor questionnaire based on
compliance where both donor and patient health are considered.
The questionnaire and the interview are the results of several
adjustments and efficient analyzes (as deeply investigated by
Gillet and Neijens), where nurses and other health professional
play a central role.
The next link is blood testing for infectious disease markers.
The first blood donor screening test for an infectious disease
agent to be routinely introduced was implemented in the early
1940s to detect a Treponema pallidum infection. Until the
discovery and characterization of the Australia antigen (HBsAg)
in 1968, no further tests were implemented. Up to the early 1990s
many blood products were contaminated with HIV, HBV, or
HCV, which consequently resulted in many transfusion-related
infections. Following the AIDS scandal during which thousands
of blood product recipients were infected, there has been a
vast increase in specific and elaborated measures to prevent
such dramatic infectious disease transmissions. These include the
introduction of a sophisticated donor questionnaire, a rigorous
disinfection of the skin associated with the elimination of the first
few milliliters of the collection in order to decrease to load of
skin-related bacterial contamination, the leucodepletion as a toll
to eliminate intracellular microbes—beside the reduction of the
immunogenicity and of the storage lesions of blood components,
highly sensitive and specific serological tests and finally new test
technologies such as nucleic acid testing (NAT) and pathogen
reduction (PR). All these measures have greatly increased the
safety of blood products in relation to the transmission of
pathogens. In the last decade there has been a new focus on
the so-called (re)-emerging infectious agents, such as West-Nile
virus, Chikungunya virus, Dengue virus, and Zika virus. The
interest in these diseases led to the introduction of new measures
to prepare the blood donation community for the potential
emergence of these threats. The current situation in the Latin
American continent is described by Levi. Particularly in Europe
the viral agents Parvovirus B19, Cytomegalovirus (CMV) and
more recently Hepatitis E virus (HEV) have become an important
issue. Juhl and Hennig and Dreier et al. show how Parvovirus
B19 and HEV, respectively, are relevant in the safety of blood
components. Despite the measures described above, there are
still several issues which need to be addressed. For instance,
it is often not clear whether a pathogen is really transmitted
by blood products. If the agent is shown to be transmitted,
then the question of the infectious dose needs to be addressed.
Both, the transmission and the infectious dose, are essential
issues which must be evaluated prior to the design of a specified
test strategy. Furthermore, the importance of the virus load, as
exemplified for HBV, is addressed by Candotti and Laperche.
PR has recently become standard practices in many countries
either for platelet concentrates and/or plasma resulting in safer
blood products. It remains to be seen whether PR of whole
blood and/or the automation of the procedure might, in the
future, increase the efficiency. With the progressive introduction
of various PR technologies, there is place for discussions how
these technologies will either complement or replace the existing
screening strategies. Seltsam reviewed in a very informative
manner the recent developments in the PR of blood products
completed by a comprehensive description of the molecular
impact in platelets by Schubert et al. Particularly the possible
implementation of an automated PR system of whole blood will
lead to debates whether the current highly sensitive NAT systems
required or whether less sensitive pool NAT systems will be
sufficient. It is also possible to envisage an approach by using
multiplexed viruses detection in one NAT reaction in order to
save costs.
Ultimately it has to be clarified how, when and why new
measures should be introduced. Appropriate decisions must
be made together with all the various stakeholders involved,
based not only on safety points but also on clear cost-benefit
considerations. A well-adjusted safety policy will not be easy to
define and certainly will not satisfy everyone involved in the
global process. The balance between maximal or optimal safety
and the high costs are relevant topics: the subject is elegantly
discussed by Zaaijer in his open minded review.
UNDERSTANDING THE BLOOD
PRODUCTS QUALITY
PR systems (as stated above) have recently become standard in
many countries for platelet concentrates and plasma resulting in
safer blood products (Seltsam; Schubert et al.). This innovation
is a typical example where the processing impacts several
biological functions of blood products. In-depth investigations
of RBCs, platelet and plasma components have been carried
out during the last decades. For instance, the impact of PR
on platelets (reviewed by Schubert et al.) illustrates the role
and the advantage of these investigations in understanding the
preparation of blood for transfusion. The platelets thus produced
exhibit different properties (we meet once again the diversity)
that might be particularly relevant for recipients. Another
interesting aspect of platelets physiology was pointed out by
Handtke et al. They reviewed the relevance of cell subpopulations
for transfusion which is of importance knowing that the method
of collection and processing might enrich or deplete specific
phenotypes. The next cutting-edge innovation is clearly the
in vitro production of platelets. This field of investigation [as
it has been achieved a few years ago for RBCs (4)] is clearly
moving forward and Strassel et al. reviewed the advancements
and challenges in this promising facet of transfusion
medicine that could deeply transform the whole blood chain
supply.
RBCs have been also deeply investigated during the last
decades and the related articles illustrate here the achievements
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reached so far. Nemkov et al. have recently focused on
metabolism of citrate in mature RBCs. Their interesting
metabolomic investigation reports the consumption of citrate
and other carboxylates in function of hypoxia. Using a similar
approach, the same group in collaboration with Kriebardis
and colleagues (Reisz et al.) highlighted the consequences on
storage parameters when blood was collected from glucose
6-phosphate dehydrogenase (G6PD)-deficient donors. These
investigations are not only relevant for better understanding
of pathophysiological behaviors of RBCs but also for the
investigation of storage lesions, which are the consequences
of a cascade of events (5). At the other end of metabolism
rerouting, cell morphology shifts from a discocyte to a spherocyte
with an impact on deformability. Several tools are available
to quantify these modifications and Roussel et al. described a
simple and elegant method to assess volume and morphological
parameters using a microfluidic chamber coupled to fluorescence
exclusion without RBC pre-treatment. These approaches will
be useful for as well the future developments of preservation
strategies as the physiological understanding of RBC biology.
The assessment of transfused RBC quality (knowing the
deleterious effects of processing and storage) in clinical trials
is required. The gold standard is obviously the 24-h post-
transfusion recovery that is one of the specifications that has
to be met in order to validate red cell concentrates (RCCs)
for transfusion. Nevertheless, the different methods reviewed
by Roussel et al. exhibited weaknesses and other markers of
storability would be a plus in validation procedures and clinical
trials.
PATIENTS
Last but not least, we should never forget that blood products
are designed and processed for transfusion purposes. The role
of RBCs in neurodegeneration was explored in a perspective
paper by Bosman. The pathological context of the disease (here
neuroacanthocytosis) and the RBC abnormality can affect brain
oxygenation; the question on treatments that could reduce RBC
defects is thus opened. The previously mentioned metabolomic
approach on G6PD-deficient donors was also applied to assess
the status of fresh frozen plasma (FFP) derived from these
donors by Tzounakas et al. Their results highlighted different
properties compared to standard FFP which might deserve
the transfusion of plasma taking advantage of antioxidant and
procoagulant activities. The transfusion of FFP has his pro and
cons clinicians and recent studies plaid for beneficial effects of
plasma. In this sense, Barelli and Alberio interestingly discussed
the role of FFP in massive bleeding and its ability to preserve
the endothelial glycocalyx structure and function. As for the
platelet transfusion where their hemostatic role is obvious,
Sut et al. pointed out in a detailed review the inflammatory
potential of stored platelets and their involvement in adverse
reactions.
Another important adverse transfusion event is
alloimmunization resulting from the phenotypic disparities
between donor and recipient. Repeated blood transfusions can
result in the production of alloantibodies against one or more
RBC antigens, which in turn complicate subsequent transfusions.
Such events often lead to difficulties in providing a compatible
RCC for a future transfusion, which can lead to an increased
morbidity and mortality in transfusion-dependent patients
(as in sickle cell anemia). Furthermore, due to the increasing
heterogeneity of populations, the matching of the labile blood
components for patients of different ethnicities is becoming
increasingly awkward. van Sambeeck et al. reviewed the future
approaches in blood screening and patient compatibility of the
blood products to improve targeted donor recruitment strategies.
The thematic covered in this research topic on “Transfusion
Medicine and Blood” is all but exhaustive: however, it represents
recent advances and approaches along the transfusion chain,
including specific preparations of blood-derived products such as
the serum eye drop reviewed here by Drew et al. to treat dry eye
syndrome. The clinical trials, the future of universal blood and all
the therapeutics aspects of blood collection and cellular therapies
were not included here but are part of our everyday life. The aims
of all these researches are always to provide safe and adapted
blood products for patients in a sustainable financial context,
while keeping a suitable pool of health donors. It is interesting to
point out that several papers in this collection consider the costs
in their discussion since the margins are quite narrow to improve
the whole chain.
In this context, research and development strategies are of
primary importance to assist and shape the future of transfusion,
and to convince stakeholders and other decision-makers. As
in other scientific and medical fields, the economic pressure is
important and it is difficult to grant research program. Moreover,
the public funds are not always available for transfusion medicine
and blood banks have to contribute to finance R&D by themself.
Different organizations are in place worldwide partly supported
by the academia (around two third of the authors here are
employed in academia or university hospital) or 100% by blood
banks. It is noteworthy that the investments are compulsory to
shape the future and we cannot ignore the vast developments
and innovation the R&D can initiate and support. Transfusion
medicine has definitively been moving (even fighting against
dogma since the 17th, dogma that still exist in different forms)
and the science of blood transfusion is at the heart of medicine.
Because, as already mentioned, transfusion medicine is both a
personalized as well as a precision medicine.
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